Cargando…

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

A genome-wide association (GWA) study of treatment outcomes (response and remission) of selective serotonin reuptake inhibitors (SSRIs) was conducted using 529 subjects with major depressive disorder (MDD). While no SNP associations reached the genome-wide level of significance, 14 SNPs of interest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Yuan, Biernacka, Joanna M., Hebbring, Scott, Chai, Yubo, Jenkins, Gregory D., Batzler, Anthony, Snyder, Karen A., Drews, Maureen S., Desta, Zeruesenay, Flockhart, David, Mushiroda, Taisei, Kubo, Michiaki, Nakamura, Yusuke, Kamatani, Naoyuki, Schaid, Daniel, Weinshilboum, Richard M., Mrazek, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2012
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941038/ https://www.ncbi.nlm.nih.gov/pubmed/22907730 http://dx.doi.org/10.1038/tpj.2012.32

Ejemplares similares

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
por: Gupta, M, et al.
Publicado: (2016)

Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Amare, Azmeraw T., et al.
Publicado: (2018)

Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
por: Liu, Duan, et al.
Publicado: (2017)

Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
por: Liu, Mohan, et al.
Publicado: (2012)

Empirical evaluation of variant calling accuracy using ultra-deep whole-genome sequencing data
por: Kishikawa, Toshihiro, et al.
Publicado: (2019)

Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers
por: Li, Liang, et al.
Publicado: (2009)

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
por: Qin, Sisi, et al.
Publicado: (2019)

Multivariate models to detect genomic signatures for a class of drugs: application to thiopurines pharmacogenomics
por: Fridley, B L, et al.
Publicado: (2012)

Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
por: Nguyen, Thanh Thanh L., et al.
Publicado: (2021)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2015)

The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response
por: Biernacka, J M, et al.
Publicado: (2016)

Editorial: Big Data, Pharmacogenomics and Real-World Research in Pharmacology
por: Wei, James Cheng-Chung, et al.
Publicado: (2020)

Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
por: Biernacka, Joanna M., et al.
Publicado: (2021)

Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021)

Haplotypes with Copy Number and Single Nucleotide Polymorphisms in CYP2A6 Locus Are Associated with Smoking Quantity in a Japanese Population
por: Kumasaka, Natsuhiko, et al.
Publicado: (2012)

Using a pharmacogenomic algorithm to guide the treatment of depression
por: Hall-Flavin, D K, et al.
Publicado: (2012)

TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
por: Ho, Ming-Fen, et al.
Publicado: (2020)

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
por: Liu, Duan, et al.
Publicado: (2018)

ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population
por: Fukunaga, Koya, et al.
Publicado: (2016)

Pharmacogenomics in Practice
por: Wang, Liewei, et al.
Publicado: (2019)

Clinical pharmacology of serotonin selective reuptake inhibitors /
por: Preskorn, Sheldon
Publicado: (1996)

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia
por: Welsch, Patrick, et al.
Publicado: (2018)

Selective serotonin reuptake inhibitors and Alzheimer’s disease
por: Mdawar, Bernadette, et al.
Publicado: (2019)

Genome Wide Association Study of Age at Menarche in the Japanese Population
por: Tanikawa, Chizu, et al.
Publicado: (2013)

Serotonin syndrome triggered by postoperative administration of serotonin noradrenaline reuptake inhibitor (SNRI)
por: Takata, Junko, et al.
Publicado: (2019)

Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome‐Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2
por: Dudenkov, Tanda M., et al.
Publicado: (2019)

Metformin Pharmacogenomics: Biomarkers to Mechanisms
por: Wang, Liewei, et al.
Publicado: (2014)

Correction: Genome Wide Association Study of Age at Menarche in the Japanese Population
por: Tanikawa, Chizu, et al.
Publicado: (2013)

Effect of Serotonin Reuptake Inhibitors on Pulmonary Hemodynamics in Humans
por: Pleym, Hilde, et al.
Publicado: (2011)

Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis
por: Wozniak, Greta, et al.
Publicado: (2011)

Heart Rate Recovery and Selective Serotonin Reuptake Inhibitors
por: Cerit, Levent
Publicado: (2016)

Selective serotonin reuptake inhibitor-induced galactorrhea with hyperprolactinemia
por: Bhattacharjee, Subir, et al.
Publicado: (2021)

Confounding by Indication in Studies of Selective Serotonin Reuptake Inhibitors
por: Lee, Jimin, et al.
Publicado: (2022)

Psychiatric pharmacogenomic testing in clinical practice
por: Mrazek, David A.
Publicado: (2010)

Transient Serotonin Syndrome Caused by Concurrent Use of Tramadol and Selective Serotonin Reuptake Inhibitor
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis
por: Gosmann, Natan Pereira, et al.
Publicado: (2021)

The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials
por: Azizi, Marzieh, et al.
Publicado: (2022)

Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors
por: Cosci, Fiammetta, et al.
Publicado: (2022)

A Penalized Mixture Model Approach in Genotype/Phenotype Association Analysis for Quantitative Phenotypes
por: Li, Lang, et al.
Publicado: (2010)

Overcoming Resistance to Selective Serotonin Reuptake Inhibitors: Targeting Serotonin, Serotonin-1A Receptors and Adult Neuroplasticity
por: Vahid-Ansari, Faranak, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hkafn4mcoea096o7n96tboglji